ACR Congress Review 2019

Kremer J, Van den Bosch F, Rubbert-Roth A, Radominski S, Burmester G, Camp H, Meerwein S, Howard M, Song Y, Zhong S, Combe B.
A comparison of upadacitinib plus methotrexate and upadacitinib plus other csDMARDS in patients with rheumatoid arthritis: an analysis of
two phase 3 studies. Arthritis Rheumatol. 2019; 71 (suppl 10):A524.
Lauper K, Mongin D, Bergstra S, Choquette D, Codreanu C, Elkayam O, Hyrich K, Iannone F, Kristianslund E, Kvien T, Leeb B, Lukina G,
Nordström D, Onen F, Pavelka K, Pombo-Suarez M, Rotar Z, Santos M, Strangfeld A, Courvoisier D, Finckh A. Heterogeneity in the pattern
of use of JAK-inhibitors between countries participating in an international collaboration of registers of rheumatoid arthritis patients (the
JAK-pot study). Arthritis Rheumatol. 2019; 71 (suppl 10):A1420.
Lent S, Sornasse T, Georgantas R, Sokolove J, McInnes I. Molecular analysis of the mode of action of upadacitinib in rheumatoid arthritis
patients: whole blood RNA expression data from the SELECT-NEXT study. Arthritis Rheumatol. 2019; 71 (suppl 10):A545.
Li L, Lu N, Lacaille D, Xie H, Esdaile J, Avina-Zubieta J. Risk of venous thromboembolism in rheumatoid arthritis patients initiating biologic
and non-biologic DMARDs, a population-based study. Arthritis Rheumatol. 2019; 71 (suppl 10):A1894.
Luissi A, Pierini F, Gandino I, Botta E, Brites F, Boero L, Martin M, Meroño T, saez S, Tetzlaff W, Sommerfleck F, Citera G, Rosa J,
Sorroche P, Soriano E. Effect of tofacitinib on the qualitative profile of high density lipoproteins molecules in patients with rheumatoid
arthritis. Arthritis Rheumatol. 2019; 71 (suppl 10):A1415.
Malaurie M, Constantin A, Degboé Y, Ruyssen-Witrand A, Barnetche T. Short-term risk of major adverse cardiovascular events or venous
thrombo-embolic events in patients with rheumatoid arthritis initiating a janus kinase inhibitor: a meta-analysis of randomised controlled
trials. Arthritis Rheumatol. 2019; 71 (suppl 10):A2358.
Matsuno H, Atsumi T, Takei S, Tamura N, Harigai M, Fujii T, Momohara S, Takahashi Y, Narii N, Tsujimoto N, Nishikawa A, Ishii T,
Yamamoto K, Kuwana M, Takagi M. Safety of baricitinib under clinical settings in patients with rheumatoid arthritis, using data from all-case
post-marketing surveillance and spontaneous reports. Arthritis Rheumatol. 2019; 71 (suppl 10):A2375.
Movahedi M, Cesta A, Li X, Keystone E, Bombardier C, Other OBRI Investigators A. Time to discontinuation of tofacitinib in rheumatoid
arthritis patients with and without methotrexate: results from a rheumatoid arthritis cohort. Arthritis Rheumatol. 2019; 71 (suppl 10):A1428.
Nash P, Greenwald M, Lin L, Yu W, Santos Estrella P, Mundayat R, Graham D, Veale D. The impact of time since first diagnosis on the
efficacy and safety of tofacitinib in patients with active psoriatic arthritis. Arthritis Rheumatol. 2019; 71 (suppl 10):A1484.
Pawar A, Desai R, Gautam N, Kim S. Risk of serious infections in tofacitinib versus other biologic drug initiators in patients with rheumatoid
arthritis: a multi-database cohort study. Arthritis Rheumatol. 2019; 71 (suppl 10):A2826.
Peterfy C, Genovese M, Song I, Friedman A, Hall S, Mysler E, Durez P, Baraliakos X, Enejosa J, Shaw T, Li Y, Chen S, Strand V. Inhibition
of structural joint damage with upadacitinib as monotherapy or in combination with methotrexate in patients with rheumatoid arthritis.
Arthritis Rheumatol. 2019; 71 (suppl 10):A547.
Pope J, Lee Y, Curtis J, Mo D, Rooney T, Xie L, Dickson C, Schlichting D, Quebe A, Cardoso A, Simon L, Taylor P. Baricitinib 4 mg and
2 mg once daily reduced pain in both patients who were opioid users and non-users in active rheumatoid arthritis: a post-hoc analysis of
phase 3 trials. Arthritis Rheumatol. 2019; 71 (suppl 10):A1880.
Price L, Pouliot P, Schmitt L. Pre-Biologic Use of janus kinase inhibitors for the treatment of rheumatoid arthritis in the United States.
Arthritis Rheumatol. 2019; 71 (suppl 10):A1445.
Ritchlin C, Ogdie A, Giles J, Gomez-Reino J, Helliwell P, Stockert L, Young P, Joseph W, Mundayat R, Graham D, Woolcott J, Romero A.
Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis. Arthritis Rheumatol. 2019; 71
(suppl 10):A1513.
Smolen J, Emery P, Rigby W, Tanaka Y, Vargas J, Damjanov N, Jain M, Sui Y, Enejosa J, Pangan A, Camp H, Cohen S. Upadacitinib as
monotherapy in patients with rheumatoid arthritis: results at 48 weeks. Arthritis Rheumatol. 2019; 71 (suppl 10):A513
Sornasse T, Sokolove J, McInnes I. Treatment with upadacitinib results in the normalization of key pathobiologic pathways in patients with
rheumatoid arthritis. Arthritis Rheumatol. 2019; 71 (suppl 10):A522.
Strand V, Pope J, Woolcott J, Rivas J, Diehl A, Liu S, Gruben D, Cohen S. MTX withdrawal in patients with RA who achieve low disease
activity with tofacitinib modified-release 11 mg once daily + MTX: An assessment of the impact on the short form-36 patient-reported
outcome. Arthritis Rheumatol. 2019; 71 (suppl 10): A1377.
Strand V, Tundia N, Friedman A, Camp H, Suboticki J, Goldschmidt D, Fernan C, Bergman M. Impact of 24- or 26-week upadacitinib
monotherapy on patient-reported outcomes in patients with moderately to severely active rheumatoid arthritis and no prior use of or an
inadequate response to methotrexate: results from two phase 3 trials. Arthritis Rheumatol. 2019; 71 (suppl 10):A1376.
Takeuchi T, Tanaka Y, Rokuda M, Izutsu H, Kaneko Y, Fukuda M, Kato D. Adverse events of special interest in patients with rheumatoid
arthritis treated with peficitinib in Asian population: pooled safety findings. Arthritis Rheumatol. 2019; 71 (suppl 10):A2403.
Takeuchi T, Tanaka Y, Rokuda M, Izutsu H, Kaneko Y, Fukuda M, Kato D, van der Heijde D. Inhibition of joint destruction in patients with
*Chairman’s Pick